NL
DE
About
We aim to improve prognosis of rare cancer patients by doing research.
Aims
Rare cancers are defined as those with an incidence of fewer than 6 per 100,000 people per year. Rare cancers account for 24% of all cancer diagnosis.
The prognosis of patients with a rare cancer is worse than that of patients with a non-rare cancer. Between 1995-1999 and 2015-2019, 5-year survival rates for rare cancers increased to a lesser extent (from 46.2% to 52.6%, i.e., 6.4%) than for common cancers (56.9% to 70.1%, i.e., 13.2%)
The mission of our research group is to improve prognosis of rare cancer patients by doing research. Examples of cancers in which our group is especially interested are:
- Sarcoma (dr. Desar)
- Uveal melanoma (dr. Bol)
- Rare cancers in general & salivary gland cancers and head and neck cancers (prof. dr. van Herpen)
- Rare gynaecological cancers (dr. Ottevanger)
- Rare GI-tract tumors (dr. Gootjes and dr. Westdorp)
We have a link with several research programs and with our phase I unit, to offer patients with rare cancers innovative medications. Furthermore, we work closely together with rare cancers patient societies.
